Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 21;10(6):1289.
doi: 10.3390/jcm10061289.

Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use

Affiliations

Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use

Avani Kathuria et al. J Clin Med. .

Abstract

Dry eye disease is a common ocular condition affecting millions of people worldwide. Artificial tears are the first line therapy for the management of dry eye disease. Artificial tear formulations contain a variety of active ingredients, biologically active excipients, and preservatives. Many of these formulations are also available as preservative-free. This study was conducted to inspect artificial tear formulations currently marketed in the United States for their active ingredients, biologically relevant excipients, and preservatives. The marketed artificial tears were examined at various US retail pharmacy chains and using the manufacturers' website to compile information about active ingredients, inactive ingredients, and preservatives. The currently marketed artificial tears can be grouped into four categories based on their active ingredients. The artificial tears also contain biologically active chemicals listed as inactive ingredients, which have osmoprotectant, humectant, and tear film lipid layer or mucous layer mimicking properties. Most artificial tears contain vanishing type preservatives such as purite or sodium perborate and safer quaternary compound polyquaternium-1. The majority of these artificial tear formulations are also available as preservative-free single dose unit. The study provides a formulary of artificial tears based on active ingredients, biologically active excipients, and the preservative-free option. The formulary should assist healthcare providers in making a stepwise and rational selection of appropriate artificial tears for patients suffering from dry eye disease.

Keywords: artificial tears; demulcents; dry eye; humectants; ophthalmic preservatives; osmoprotectants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Farrand K.F., Fridman M., Stillman I.Ö., Schaumberg D.A. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am. J. Ophthalmol. 2017;182:90–98. doi: 10.1016/j.ajo.2017.06.033. - DOI - PubMed
    1. Craig J.P., Nichols K.K., Akpek E.K., Caffery B., Dua H.S., Joo C.K., Liu Z., Nelson J.D., Nichols J.J., Tsubota K., et al. TFOS DEWS II Definition and classification report. Ocul. Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008. - DOI - PubMed
    1. Nelson J.D., Craig J.P., Akpek E.K., Azar D.T., Belmonte C., Bron A.J., Clayton J.A., Dogru M., Dua H.S., Foulks G.N., et al. TFOS DEWS II introduction. Ocul. Surf. 2017;15:269–275. doi: 10.1016/j.jtos.2017.05.005. - DOI - PubMed
    1. Akpek E.K., Amescua G., Farid M., Garcia-Ferrer F.J., Lin A., Rhee M.K., Varu D.M., Musch D.C., Dunn S.P., Mah F.S. Dry eye syndrome preferred practice pattern. Ophthalmology. 2019;126:286–334. doi: 10.1016/j.ophtha.2018.10.023. - DOI - PubMed
    1. Willcox M.D., Argüeso P., Georgiev G.A., Holopainen J.M., Laurie G.W., Millar T.J., Papas E.B., Rolland J.P., Schmidt T.A., Stahl U., et al. TFOS DEWS II tear film report. Ocul. Surf. 2017;15:366–403. doi: 10.1016/j.jtos.2017.03.006. - DOI - PMC - PubMed